Phase I Clinical Trial of Cryoimmunotherapy Against Prostate Cancer
Status:
Completed
Trial end date:
2019-08-16
Target enrollment:
Participant gender:
Summary
20 patients with invasive castration resistant prostate cancer and radiologically verified
metastases will be enrolled into the Phase I Clinical Trial. The trial is a dendritic cell
based immunotherapy. Autologous dendritic cells will be obtained by leukapheresis and
elutriation and stimulation by cytokines. The induced dendritic cells will have to pass
viability, immunophenotyping and sterility criteria and will be injected into a cryoablated
region of the primary prostate cancer tumor. The treatment is supplemented by
immunomodulatory regimens.
Phase:
Phase 1
Details
Lead Sponsor:
Alden Cancer Therapy II
Collaborators:
Haukeland University Hospital Norwegian Radium Hospital